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Background. Primary bone lymphoma (PBL) is a rare entity that has only been reviewed in one prospective and small retrospective
studies, from which it is difficult to establish treatment guidelines. We prospectively evaluated high-dose or conventional
anthracycline-cyclophosphamide dose and radiotherapy for PBL. Patients and Methods. The GOELAMS prospective multicenter
study (1986–1998) enrolled adults with localized high-grade PBL according to age and performance status (PS). Patients <60
years received a high-dose CHOP regimen (VCAP) and those ≥60 years a conventional anthracycline-cyclophosphamide regimen
(VCEP-bleomycin); all received intrathecal chemotherapy and local radiotherapy. Results. Among the 26 patients included (VCAP:
19; VCEP-bleomycin: 7), 39% had poor PS ≥2. With a median follow-up of 8 years, overall survival, event-free survival, and
relapse-free survival were 64%, 62%, and 65%, respectively, with no significant difference between treatment groups. Poor PS was
significantly associatedwith shorterOS and EFS.Conclusions. Our results confirm the efficacy of our age-based therapeutic strategy.
High-doses anthracycline-cyclophosphamide did not improve the outcome. VCEP-bleomycin is effective and well tolerated for old
patients. The intensification must be considered for patients with PS ≥2, a poor prognostic factor.
1. Introduction
Primary bone lymphoma (PBL) is a rare clinicopathological
entity accounting for about 3% of malignant bone tumors, 1%
of non-Hodgkin lymphomas (NHL), and 5% of extranodal
NHL [1–4]. In most cases, histology is diffuse large B-cell
lymphoma (DLBCL). Whether or not PBL requires specific
treatment guidelines has to be determined. Since the 1960s,
management of limited stage I-II PBL has usually consisted of
radiotherapy to the involved bone and adjacent lymph nodes
inducing at least a good local control [2, 5]. Then, adjunction
of chemotherapy has systematically been recommended to
counter the relatively high rates of relapse occurring outside
the original location after radiation alone. For advanced cases,
corresponding to disease with multiple bones localizations,
treatment can only be based on this combined-modality with
generally very good prognosis [1, 6, 7].
To date, PBL has primarily been reviewed in several
small retrospective studies and only one prospective study
[1, 4, 8–10]. Our prospective study aimed to evaluate overall
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survival (OS), event-free survival (EFS), and relapse-free
survival (RFS) after high-dose or conventional anthracycline-
cyclophosphamide regimen for adults with localized non-
Hodgkin’s PBL before rituximab era.
2. Patients and Methods
2.1. Study Design and Patient Eligibility. Patients 17–75 years
oldwith localized high-grade PBLwere enrolled in a prospec-
tive, multicenter GOELAMS study. These patients accounted
for 9.3% of the 305NHL included in the 02 and 03GOELAMS
trials between March 1986 and May 1998 and gave their
written informed consent to participate. The histological
diagnosis was confirmed on an excision biopsy, in accordance
with the previous working formulation criteria [11].
Staging procedures included performance status (PS),
differential white blood-cell counts, biochemical analyses
(serum lactate dehydrogenase (LDH) and hepatic and renal
function tests), thoracic-abdominal-pelvic computed tomog-
raphy scan, bone-marrow biopsy, and cerebrospinal fluid
cytology. Human immunodeficiency virus-positive patients
were excluded. The stage was determined according to the
Ann Arbor criteria. Bulky disease was defined as a lesion
exceeding >5 cm.
2.2. Treatment Protocol. Patients <60 years old (GOELAMS
02 trial) received three cycles of the high-dose CHOP
regimen (VCAP), as follows: eldisine i.v. 3mg/m2 on day 1,
doxorubicin i.v. 60mg/m2 on day 1, cyclophosphamide i.v.
1500mg/m2 on day 1, and oral prednisone 80mg/m2/d
on days 1–5. Patients ≥60 years old (GOELAMS 03 trial)
received three cycles of a conventional anthracycline-
cyclophosphamide regimen (VCEP-bleomycin), as follows:
eldisine i.v. 3mg/m2 on day 1, farmorubicin i.v. 80mg/m2
on day 1, cyclophosphamide i.v. 750mg/m2 on day 2, oral
prednisone 50mg/m2/d on days 1–7, and bleomycin 10mg on
days 1 and 5.
For both trials, each course was repeated every 21 days
and intrathecal chemotherapy (methotrexate 15mg) was
administered with each cycle. Since January 1990, all pati-
ents have been given granulocyte-colony-stimulating factor
between chemotherapy cycles.
Onemonth after completing chemotherapy, every patient
received involved-field radiotherapy (total dose: 40Gy deliv-
ered in 20 fractions, 2 Gy/day) over 4 weeks.
2.3. Response Assessment and Follow-Up Evaluation. Treat-
ment response was determined by physical examination
and biological and radiological workup. In the GOELAMS
prospective multicenter study, complete response (CR) was
defined as the complete disappearance of all clinical, bio-
logical, and radiological evidence of disease (absence of
progressive bone lesions).The follow-up included clinical and
radiological evaluation every six months.
Survival analyses included OS, EFS, and RFS. OS was
calculated from the time of diagnosis until death from any
cause. EFS was calculated from time of diagnosis (i.e., study
entry) until disease progression, relapse, second malignancy,
and death from any cause. RFSwas calculated as survival after
achievement of CR until relapse or death.
2.4. Statistical Methods. Results are expressed as median
(range), mean ± SD, or number (%).
Survival curves were calculated using the actuarial
Kaplan-Meier method. Log-rank analysis was used to assess
the significance of differences between curves for patients
groups. Patients’ characteristics were subjected to univariate
analysis using log-rank test, before being entered into Cox
proportional hazards (multivariate analyses) regressionmod-
els, to determine prognostic factors (two sided). A 𝑃 = 0.05
was considered significant. The studied prognostic factors
are the gender, the sex, the stage, the B symptoms, the site,
the LDH level, the bulky disease, the PS, and the epidural
involvement.
All statistical analyses were conducted with the statistical
package for social sciences (SPSS Inc., Chicago, IL).
3. Results
Twenty-six patients with PBL were included in GOELAMS
02 (19/26 patients, 73%) and 03 (7/26 patients, 37%) trials
from 1986 to 1998 and their characteristics are summarized
in Table 1.
Their median age was 46 years (range 17–69) (19 patients)
and 70 years (range 65–75) (7 patients) in the GOELAMS 02
and 03 trials (cutoff of 60 years), respectively. Three patients
between 63 and 69 years old but with excellent PS were
included in the GOELAMS 02 trial by the investigators.
Overall male/female ratio was 1.6.
The main PBL site was the axial skeleton. Two patients
had bifocal bones lesions (axial and peripheral skeleton bone
lesions). Skin and subcutaneous tissues were also involved in
two patients. According to the Ann Arbor classification, 81%
of patients were stage I and 19% were stage II. Six patients of
the GOELAMS 02 trial had epidural involvement, revealed
by paraplegia which may largely explain why PS was ≥2 for
35% of the patients. Predominant histological subtypes were
diffuse, small cleaved cell lymphoma and diffuse, mixed small
and large cell according to the Working Formulation, which
correspond to DLBCL in the Working Health Organization
classification.
Except for age and bulky disease, the two trials were com-
parable for histological type, site, Ann Arbor classification, B
symptoms, and LDH (Table 1). All but one patient achieved
CR (96%). A 63-year-old patient with VCAP-resistant costal
disease died of progressive disease after 15 months. Eight
(30%) relapses occurred at a median of 2.3 years (range
0.4–6.5) after CR: two relapses in the group of the 7 older
patients and 6 in this of the 19 younger patients, which
also included 65- and 69-year-old patients. Two out of the 8
relapses occurred at the initial PBL site.
Bulky disease was observed in nine patients and four of
them relapsed. Four relapses occurred less than 2 years after
CR, three between 2.1 and 5 years and one 6.5 years after
CR. Among the six patients with epidural involvement, three
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relapsed (50%) and three were in sustained CR: two of these
three relapses occurred in situ.
Withmedian follow-up of 8 years (range 1.2–17), OS, EFS,
and RFS were 64% ± 12, 62% ± 10, and 65% ± 10 years,
respectively. OS, EFS, and RFS in the GOELAM 02 and 6 03
trials were, respectively, 66% ± 13, 59% ± 21, 62% ± 12 and
64% ± 21, 71% ± 14, 71% ± 17 with no significant difference
between the two study groups (Table 2).
According to univariate and multivariate analysis, poor
PS (≥2) was associated with significantly shorter OS and EFS
(Figure 1 and Table 2).
4. Discussion
This report summarizes the results of a prospective study
that evaluated the long-term outcome of 26 non-Hodgkin’s
PBL in adults after high-dose or conventional anthracycline-
cyclophosphamide regimen combined with radiotherapy.
Because of PBL rarity [1–4] and the heterogeneity of clinical
procedure applied for diagnosis, staging, and treatment,
controversies persist and no specific guidelines have been
established.
The predominant histological profile of diffuse large B-
cell lymphomas observed herein is consistent with published
data [9, 10, 12]. No significant survival difference among
between PLB subtypes has been observed in the literature [12,
13]. The median age was slightly higher than those reported
previously (45–50 years) [3, 9, 14], whichmay reflect inclusion
criteria. Unlike the majority of reports [1, 13, 15, 16], age did
not influence the survival parameters (response rate, relapses,
OS, RFS, progression, or EFS) of our patients. Indeed, the
relatively good tolerance of treatment probably reflects the
modulation of the chemotherapy dose according to age.
Moreover, no radiotherapy complications were observed,
certainly because of the low radiation dose delivered.
PBL was mostly diagnosed at stages I and II [9] except in
one study with more stage IV with vertebral localization [17].
The stage appeared as themost important prognostic variable
[1, 6, 8, 18]. The standard staging procedures (including
bone radiographic, bone scan, and bone magnetic resonance
imaging) may have underestimated the Ann Arbor staging.
They do not allow an evaluation of the entire skeleton which
is now optimately performed by using positron emission
tomography [19]. Indeed stage IV is a factor of poor prognosis
and probably requires an intensified treatment. An underval-
uation of the stage leads to an insufficient treatment.
Peripheral skeleton is the most common site of PBL.
However, one previous study reported high frequency of axial
skeleton locations [20], which is a remarkable characteristic
of our patients. Nevertheless PBL site did not influence OS
and EFS in our study. However, some discrepancies concern-
ing the definition of the axial involvement in the literature
make it difficult to distinguish between the prognoses of axial
skeleton versus limb involvement [2, 20].
Bulky disease was observed in 9 patients (all included
in the VCAP group), 3 of whom having paraplegia. A
pejorative impact of paraplegia has been suggested once [21].
Our univariate analysis identified a significantly unfavorable































Diffuse, mixed, small, large 4 15
Diffuse, large cleaved or not 18 69
Large cell immunoblastic 3 12
Anaplastic large-cell ANA Ki+ 1 4
Immunophenotyping
B cells 14 54
T cells 1 4
ANA Ki+ 1 4
Nonassessable 10 38















LDH: lactatedehydrogenase; N: normal; PS: performance status; IPI: inter-
national prognostic index.
Except for age and bulky disease, the two trials were comparable (no
statistical significance). Bulky disease was observed in 9 patients, all included
in the trial 02 (𝑃 = 0.02).
Six patients of the GOELAMS 02 trial had epidural involvement, revealed by
paraplegia.
impact of PS ≥2 (OS, EFS). Ourmultivariate analysis retained
poor PS but not epidural extension as being significantly
associated with shorter EFS and OS. This observation is
probably explained by relative redundancy between epidural
extension and PS, since, quite frequently in neoplasic situa-
tions, paraplegic patients had PS ≥2.
Once, the standard treatment for localized disease pri-
marily consisted of radiotherapy alone that is, from 40–
60Gy delivered within 4–6 weeks. Radiotherapy achieved
high levels of local control (80–100%) but was followed
by a high late relapse rate (50%) [5]. Then different CMT
schedules of chemotherapy and radiotherapy were proposed
[7, 15, 16, 22, 23]. It has been shown that anthracycline-
based therapy improves the response rate and prolongs OS of
patients with localized lymphomas [23]. In combination with
radiotherapy is superior to radiotherapy regarding RFS and
OS. this is may be explained by less relapse in the combined
treatment group [23]. Thus, the general PBL reputation of
poor prognosis no longer seems justified compared to other
extranodal lymphomas [2, 4, 9, 10, 24]. Notably, the OS of
disseminated PBL, that is, PBLwithmultiple locations treated
with CMT, was higher than for localized-stage disease in
some studies [15, 16, 25].
Our results confirmed the efficacy of CMT. The 96% CR
rate is excellent, and mean 5- and 10-year OS reached 79% ±
8 (22 patients) and 63% ± 12 (19 patients), respectively.
The 5- and 10-RFS at 70% ± 9 and 64% ± 10, respectively,
were similar for both GOELAMS trials. These outcomes
are not worse than those for 325 localized aggressive NHL
that were treated in another GOELAMS trial [26] and
confirm data suggested by comparable—although generally
not randomized—published studies [6, 7, 13, 15, 16, 23].
We did not observe any significant difference between the
stages I and II or normal versus high LDH levels. However,
some prognostic criteria for localized aggressive NHL do
not apply to PBL [2]. In our study, modulation of the
anthracycline-cyclophosphamide dose did not significantly
influence survival parameters (response, relapses, death, OS,
RFS, progression, or EFS) for either group.
We observed a 30% relapse rate. Among them, seven
relapses concerned pelvic localization, including three
patients with paraplegia. A higher relapse rate of axial
localization was reported previously [14, 27], leading once to
a poor OS [14]. Although local control appears to be good,
we think that systemic treatment can be further improved.
Because of the period of recruitment, the potential benefit of
Table 2: Univariate and multivariate analyses of characteristics
affecting survival of adults with non-Hodgkin primary bone lym-
phoma.
Characteristics Univariate analysis Multivariate analysis
mean ± SD 𝑃 𝑃
10-year OS, %
Trial
02 66 ± 13 ns ns
03 64 ± 21
Epidural extension
No 75 ± 11 ns ns
Yes 33 ± 25
PS ≥2
No 86 ± 10 0.046 ns
Yes 28 ± 21
10-year EFS, %
Trial
02 59 ± 21 ns ns
03 71 ± 14
Epidural extension
No 66 ± 11 ns ns
Yes 50 ± 20
PS ≥2
No 79 ± 11 0.038 0.018
Yes 33 ± 17
OS: overall survival; PS: performance status; EFS: event-free survival; ns: not
significant.
Other studied factors (gender, stage, B symptoms, site, lactatedehydrogenase
level, and bulky disease) do not have significantly statistical prognosis.
adding an anti-CD20monoclonal antibody, which seemed to
be advantageous against PBL in one study [28], could not be
tested here. Increasing the number of chemotherapy cycles
alternating regimen cycles is another option.
The high paraplegia rate (6 patients, 23%) observed in
our population merits attention. Epidural localization with
paraplegia was associated with shorter OS (33% ± 25) but
not statistically significant (OS of patients without paraplegia
75% ± 11, 𝑃 = 0.18). However, of the seven deaths recorded,
three were of patients with paraplegia. Among the six patients
with paraplegia, three relapsed and two of these three relapses
occurred in situ. Only 25% of the patients without epidural
involvement relapsed. The poor prognosis of epidural PBL
was reported in several studies [13, 29] with only one
exception [30].
In summary, our results confirmed the efficacy of CMT
against localized PBL. The systemic arm of CMT remains
insufficient, in light of the high late relapse rate. The two
schedules, the conventional VCEP-b and the high doseVCAP
chemotherapy, are different in terms of drug dosages and
for the type of anthracycline and the absence of bleomycin.
VCEP-bleomycin regimen is effective, tolerated for older
patients and high-dose anthracycline-cyclophosphamide did
not improve the outcome.
But because of the period of recruitment of our prospec-
tive study, the potential benefit of an anti-CD20 monoclonal




























Figure 1: Overall survival curves of adults with non-Hodgkin
primary bone lymphoma as a function of their performance status
(PS).
antibody is not tested. However themajority of PBL histology
is B phenotype. Since 10 years, in these situations, the stan-
dard of chemotherapy included an anti-CD20 monoclonal
antibody.Themanagement of limited stage I-II PBL probably
consists of 3 to 4 cycles of chemotherapy adding an anti-CD20
monoclonal antibody. More chemotherapy cycles should be
considered for the patients with a high IPI score, even if the
impact of IPI score is not yet validated in PBL. Radiotherapy
is valid for local control and intensification remains discussed
in the localized stages. But the staging must be precise. The
staging procedure should now include positron emission
tomography (PET) to see the entire skeleton, what it is not
the case of our study. Furthermore, for bone lymphoma, the
assessment of CR with CT scan is onemajor problem, the use
of the PET allowed to solve.
On the other hand, epidural disease and PS ≥2 are factors
of poor prognosis. New therapeutic strategies should be con-
sidered for these patients: addition of anti-CD20monoclonal
antibody,more chemotherapy cycles, and/or their alternation
and intensification.
5. Clinical Practice Point
(1) Treatment guidelines do not exist in PBL, because it is
a rare entity and thus randomized prospective clinical
trials are lacking.Nevertheless, combined chemother-
apy and radiotherapy strategies have improved the
management of PBL in particular in cases of advanced
disease.
(2) In this study, we review the clinical outcome of 26
patients with previously untreated PBL, all receiv-
ing anthracycline-cyclophosphamide containing reg-
imen and consolidative radiation therapy. With
median follow-up of 8 years, overall survival, event-
free survival, and relapse-free survival were, respec-
tively, 64%, 62%, and 65%. Poor PS was associated
with shorter OS and EFS. High dose anthracycline-
cyclophosphamide did not improve outcome.
(3) In our opinion, combined chemotherapy and radio-
therapy, nowadays probably in association with mon-
oclonal anti-CD20 infusion, are efficace treatment for
PBL. Intensified treatment must be considered for
patients with PS≥2.Moreover, new staging procedure
including positron emission tomography should be
now included.
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